TD Cowen analyst Yaron Werber reiterated a Buy rating on Stoke Therapeutics (NASDAQ: STOK).The analyst commented, "New Ph1/2a updated data ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE